Latest Adrenocorticotropic hormone Stories
DALLAS, April 13, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015" to its store.
SAN DIEGO, Jan. 16, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc.
RnRMarketResearch.com adds “EpiCast Report Cushing’s Syndrome - Epidemiology Forecast to 2023” to its store.
SALT LAKE CITY, April 16, 2014 /PRNewswire/ -- Jessica Smith is skating her way into history.
MADISON, Wis., April 7, 2014 /PRNewswire/ -- The European Medicines Agency (EMA) has granted Minor Use Minor Species (MUMS) designation for Nexcyon's adrenocorticotropin (ACTH), a synthetic
Genetic research that will be published tomorrow in the New England Journal of Medicine suggests to Dr. André Lacroix, professor at the University of Montreal, that clinicians' understanding and treatment of a form of Cushing's syndrome affecting both adrenal glands will be fundamentally changed, and that moreover, it might be appropriate to begin screening for the genetic mutations that cause this form of the disease.
Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder.
After we sense a threat, our brain center responsible for responding goes into gear, setting off a chain of biochemical reactions leading to the release of cortisol from the adrenal glands.
Scientists now have a better understanding of the way that stress impacts the brain.
Cushing’s disease is a hormone disorder that causes many symptoms, such as high blood pressure, fat accumulation, osteoporosis and ultimately ending in death.
- Growing in low tufty patches.